vertebrae development associatedGenealiases: C14orf115 · vertnin
Q-omics provides the consensus-scored VRTN profile across patient tissues and cancer cell-line models. VRTN expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, VRTN is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, VRTN RNA expression shows 9,750 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, HNSC, and TGCT as cancer lineages where VRTN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VRTN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VRTN survival associations across molecular data types. VRTN RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VRTN RNA expression–survival associations across cancer types. High VRTN expression shows unfavorable associations in LIHC and ACC, but favorable associations in ESCA, READ, HNSC and OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for VRTN RNA expression.
This table summarizes VRTN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for VRTN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VRTN shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, LUAD, STAD and COAD. The HNSC box plot shows higher VRTN RNA expression in tumor versus normal tissue (log2 FC = +0.086, t-test p = .010).
This table shows molecular features associated with VRTN in patient tissues and cancer cell lines. In patient samples, VRTN shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, VRTN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
